Drugs / TV-44749
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06253546 | Mar 2024 → Jun 2025 | schizophrenia | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06315283 | Mar 2024 → Aug 2025 | schizophrenia | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05693935 | Jan 2023 → Mar 2024 | schizophrenia | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TV-44749 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06253546 ↗ |
| Route | Subcutaneous | “TV-44749 is a novel, long-acting, subcutaneous (SC) olanzapine injection” PMID 41632432 ↗ Feb 2026 |